on SHS Gesellschaft Für Beteiligungsmanagement MbH
SHS Capital Plans Sale of PathoQuest to Charles River Laboratories
SHS Capital, a private equity firm specializing in healthcare, plans to sell PathoQuest to Charles River Laboratories. PathoQuest, based in Paris, excels in Next Generation Sequencing (NGS)-based quality control for biopharmaceuticals. This acquisition aims to merge PathoQuest's NGS expertise with Charles River's global capacity, promoting advanced, animal-free biotesting.
The sale symbolizes a significant step in PathoQuest's development, highlighting its growth and international expansion. PathoQuest has focused on NGS-based viral safety and genetic testing, boosting its operations and establishing a second GMP-compliant facility in the US. PathoQuest CEO Jean-François Brepson views the deal as a strategic advancement.
This transaction marks SHS Capital's successful investment strategy. PathoQuest's revenue quadrupled since SHS's involvement, showing the effectiveness of their operational and commercial enhancements.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all SHS Gesellschaft Für Beteiligungsmanagement MbH news